Correlation Between InMed Pharmaceuticals and Champions Oncology
Can any of the company-specific risk be diversified away by investing in both InMed Pharmaceuticals and Champions Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining InMed Pharmaceuticals and Champions Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between InMed Pharmaceuticals and Champions Oncology, you can compare the effects of market volatilities on InMed Pharmaceuticals and Champions Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in InMed Pharmaceuticals with a short position of Champions Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of InMed Pharmaceuticals and Champions Oncology.
Diversification Opportunities for InMed Pharmaceuticals and Champions Oncology
-0.31 | Correlation Coefficient |
Very good diversification
The 3 months correlation between InMed and Champions is -0.31. Overlapping area represents the amount of risk that can be diversified away by holding InMed Pharmaceuticals and Champions Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Champions Oncology and InMed Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on InMed Pharmaceuticals are associated (or correlated) with Champions Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Champions Oncology has no effect on the direction of InMed Pharmaceuticals i.e., InMed Pharmaceuticals and Champions Oncology go up and down completely randomly.
Pair Corralation between InMed Pharmaceuticals and Champions Oncology
Considering the 90-day investment horizon InMed Pharmaceuticals is expected to under-perform the Champions Oncology. In addition to that, InMed Pharmaceuticals is 1.91 times more volatile than Champions Oncology. It trades about -0.25 of its total potential returns per unit of risk. Champions Oncology is currently generating about 0.12 per unit of volatility. If you would invest 398.00 in Champions Oncology on August 29, 2024 and sell it today you would earn a total of 35.00 from holding Champions Oncology or generate 8.79% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
InMed Pharmaceuticals vs. Champions Oncology
Performance |
| Timeline |
| InMed Pharmaceuticals |
| Champions Oncology |
InMed Pharmaceuticals and Champions Oncology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with InMed Pharmaceuticals and Champions Oncology
The main advantage of trading using opposite InMed Pharmaceuticals and Champions Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if InMed Pharmaceuticals position performs unexpectedly, Champions Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will offset losses from the drop in Champions Oncology's long position.| InMed Pharmaceuticals vs. Quoin Pharmaceuticals Ltd | InMed Pharmaceuticals vs. Allarity Therapeutics | InMed Pharmaceuticals vs. Virax Biolabs Group | InMed Pharmaceuticals vs. Biodexa Pharmaceticals |
| Champions Oncology vs. Bright Minds Biosciences | Champions Oncology vs. HP Inc | Champions Oncology vs. Intel | Champions Oncology vs. Chevron Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Complementary Tools
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |